Published in J Clin Gastroenterol on October 23, 2002
Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog (2006) 3.65
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology (2011) 1.61
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis (2008) 1.55
Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon (2012) 1.47
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut (2010) 1.47
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Cancer incidence in the south Asian population of California, 1988-2000. J Carcinog (2005) 1.41
CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology (2009) 1.40
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol (2005) 1.38
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer (2009) 1.38
Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol (2005) 1.35
Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut (2005) 1.34
Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells (2009) 1.33
Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem (2011) 1.32
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol (2008) 1.30
Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol (2004) 1.27
Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol (2006) 1.25
Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol (2006) 1.25
The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology (2009) 1.21
Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol (2003) 1.20
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer (2006) 1.18
The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer (2007) 1.17
A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol (2012) 1.16
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer (2010) 1.13
Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation (2008) 1.13
Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol (2012) 1.10
Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer (2011) 1.09
Hepatocellular carcinoma in the world and the middle East. Middle East J Dig Dis (2010) 1.07
Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res (2009) 1.07
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (2010) 1.05
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res (2014) 1.05
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci (2008) 1.03
Little response of cerebral metastasis from hepatocellular carcinoma to any treatments. J Korean Neurosurg Soc (2010) 1.02
Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01
Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol (2006) 0.99
Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol Int (2007) 0.99
Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) (2005) 0.98
Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. BMC Cancer (2013) 0.98
Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 0.97
Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterol (2010) 0.97
Management of hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.96
Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon (2011) 0.95
Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging (2010) 0.94
Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol (2013) 0.93
Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg (2011) 0.93
Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology (2012) 0.92
Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin (2010) 0.92
Liver transplantation in the ethnic minority population: challenges and prospects. Dig Dis Sci (2009) 0.92
Systematic analysis of enhancer and critical cis-acting RNA elements in the protein-encoding region of the hepatitis C virus genome. J Virol (2013) 0.91
Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients. World J Gastroenterol (2005) 0.91
Effect of ultrasound-guided radiofrequency ablation in incompletely treated hepatocellular carcinoma after transcatheter arterial chemoembolization. Korean J Radiol (2012) 0.91
Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.91
Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol (2012) 0.91
A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production. Hepatology (2012) 0.91
Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. PLoS One (2013) 0.91
Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat (2011) 0.90
B vitamins deficiency and decreased anti-oxidative state in patients with liver cancer. Eur J Nutr (2007) 0.90
Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol (2011) 0.90
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget (2015) 0.90
Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J Cancer Res Clin Oncol (2013) 0.89
Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway. PLoS One (2014) 0.89
Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol (2014) 0.89
Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg (2010) 0.89
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget (2015) 0.88
Human Schistosomiasis mansoni associated with hepatocellular carcinoma in Egypt: current perspective. J Parasit Dis (2014) 0.88
Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit (2013) 0.87
Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J (2011) 0.86
Histone-modifying genes as biomarkers in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.86
Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) Detection and its Grading on 3T MRI: A Prospective Study. J Clin Exp Hepatol (2016) 0.85
Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol (2004) 0.85
Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects. Biomed Res Int (2013) 0.85
Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther (2013) 0.85
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One (2013) 0.84
Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol (2011) 0.84
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS One (2015) 0.84
Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist (2013) 0.83
Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr (2011) 0.83
Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells. Onco Targets Ther (2012) 0.83
Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol (2015) 0.82
The homeobox gene HLXB9 is upregulated in a morphological subset of poorly differentiated hepatocellular carcinoma. Virchows Arch (2011) 0.82
Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci (2012) 0.82
Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer (2007) 0.82
Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. BMC Res Notes (2008) 0.82
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget (2014) 0.82
RNAa-mediated overexpression of WT1 induces apoptosis in HepG2 cells. World J Surg Oncol (2012) 0.82
Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol (2009) 0.82
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. Int J Mol Sci (2015) 0.81
Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer (2010) 0.81
The NS5A-binding heat shock proteins HSC70 and HSP70 play distinct roles in the hepatitis C viral life cycle. Virology (2014) 0.81
Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm? Infect Agent Cancer (2012) 0.80
Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics (2010) 0.80
Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol (2014) 0.80
Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther (2015) 0.80
A survey on herbal management of hepatocellular carcinoma. World J Hepatol (2011) 0.80